|
|
|
| Clinical effects of dydrogesterone combined with aromataseinhibitor for treating patients with endometriosis and its influence on serum levels of CA125, MMP-3 and VEGF |
| Nanyang Central Hospital, Nanyang, Henan Province |
|
|
|
|
Abstract Objective:To investigate the clinical value of dydrogesterone combined with aromataseinhibitor for treating patients with endometriosis. Methods: A total of 104 patients with endometriosis treated in Nanyang central hospital from Oct 2015 to Oct 2017 were selected as study subjects, and all included patients were divided control group and observation group (52 patients in each group) by the random digital table. The patients in control were treated by dydrogesterone, and the patients in observation group were treated letrozole (byaromataseinhibitor) except by dydrogesterone. The effects of treatment, the changes of serum levels of carbohydrate antigen 125 (CA125), matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF) and sex hormone of patients in the two groups were observed before treatment and 6 months after treatment. The incidence of adverse reactions during the medication of patients in the two groups were also recorded. Results: The total effective rate of patients in observation group was 94.2%, which was statistically significant higher than that of patients (80.8%) in control group (P< 0.05). There were no significant different in serum levels of CA125, MMP-3, VEGF and sex hormone between the two groups before treatment (P>0.05), but the levels of serum CA125, MMP-3, VEGF and sex hormone of all patients had decrease after treatment. After treatment, the levels of serum CA125, MMP-3, VEGF, follicle stimulating hormone (FSH), estradiol (E2) and luteinizing hormone (LH) of patients in observation group were statistically significant lower than those of patients in control group (P<0.05). The incidence of adverse reactions during medication in observation was 17.31%, which had no statistically significant different to that (15.38%) in control group (P>0.05). Conclusion: The dydrogesterone combined with aromataseinhibitor for treating patients with endometriosis has significant effect, which can significantly reduce the levels of serum CA125, MMP-3, VEGF, can improve the status of sex hormones, and has better safety.
|
|
|
|
|
|
|
|
|
